Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
September 07 2016 - 7:39AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is
developing a next-generation treatment for posttraumatic stress
disorder (PTSD), announced today that it will present at the Rodman
& Renshaw 18th Annual Global Investment Conference being held
September 11-13, 2016 in New York, NY.
Seth Lederman, M.D., president and chief
executive officer of Tonix, will provide a corporate update and an
overview of Tonix’s PTSD clinical program. Tonix recently
announced a successful end-of-phase 2 meeting with the U.S. Food
and Drug Administration (FDA) and also positive data from its
randomized, double-blind, placebo-controlled Phase 2 AtEase
clinical trial evaluating TNX-102 SL in military-related PTSD, and
Dr. Lederman will discuss expected next steps for this program.
Event: |
|
|
|
Rodman & Renshaw 18th Annual Global
Investment Conference |
Date: |
|
|
|
Tuesday, September 13, 2016 |
Time: |
|
|
|
11:40 AM (Eastern Time) |
Location: |
|
|
|
Lotte New York Palace Hotel, New York, NY |
The presentation will be webcast live and remain
available for 90 days following the presentation. To access
the webcast, please visit the Events tab of the Investor Relations
section of Tonix’s website at www.tonixpharma.com.
TNX-102 SL is an Investigational New Drug and has not been
approved for any indication.
About Tonix Pharmaceuticals Holding Corp.
Tonix is developing next-generation medicines for common
disorders of the central nervous system, with its lead program
focusing on PTSD. This disorder is characterized by chronic
disability, inadequate treatment options, high utilization of
healthcare services, and significant economic burden. This press
release and further information about Tonix can be found at
www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
substantial competition; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of
government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and risks
related to failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report on Form 10-K for the year ended
December 31, 2015, as filed with the Securities and Exchange
Commission (the “SEC”) on March 3, 2016, and future periodic
reports filed with the SEC on or after the date hereof. All of
Tonix's forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date hereof.
Contacts
Bradley J. Saenger, CPA
Chief Financial Officer
investor.relations@tonixpharma.com
(212) 980-9155 x107
Jessica Smiley
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9155 x185
Edison Advisors (investors)
Tirth Patel
tpatel@edisongroup.com
(646) 653-7035
Dian Griesel Int’l (media)
Susan Forman / Laura Radocaj
sforman@dgicomm.com
iradocaj@dgicomm.com
(212) 825-3210
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024